Seattle biotech company Immune Design has raised $30 million in funding and filled a key executive position.
Immune design (Nasdaq: IMDZ) in September raised $30.3 million in public equity and a month later appointed Dr. Sergey Yurasov as senior vice president of clinical development and chief medical officer to continue building out the company's drug pipeline.
“This financing along with our revenue for the year provides Immune Design with a runway into the second half of 2018,” said CEO Carlos…
Seattle biotech company Immune Design has raised $30 million in funding and filled a key executive position.
Immune design (Nasdaq: IMDZ) in September raised $30.3 million in public equity and a month later appointed Dr. Sergey Yurasov as senior vice president of clinical development and chief medical officer to continue building out the company's drug pipeline.
“This financing along with our revenue for the year provides Immune Design with a runway into the second half of 2018,” said CEO Carlos…